Objective To investigate the expression of circRNA_0001445 in plasma in senile osteoporosis(SOP)and its clinical significance.Methods Patients hospitalized in the Department of Geriatric,the First People's Hospital of Changzhou from November 2020 to May 2022 were collected.All subjects were measured bone mineral density(BMD)by dual-energy X-ray absorptiometry(DXA)and divided into SOP group,osteopenia group and normal bone mass group according to BMD level.The clinical data and circRNA_0001445 expression levels were compared in each group.The correlation between circRNA_0001445 and BMD was analyzed by Pearson correlation analysis.The risk factors of SOP were analyzed by binary logistic regression.The diagnostic value of circRNA_0001445 in SOP was analyzed by receiver operating characteristic(ROC)curve.The changes of circRNA_0001445 expression levels before and after treatment was compared by paired-samples t test or paired-samples rank sum test.Results A total of 150 patients were included in this study,each group had 50 samples.The expression of circRNA_0001445 in SOP group(0.58±0.30)was significantly lower than that in osteopenia group(0.88±0.35)and normal bone mass group(1.15±0.62),P<0.001;Pearson correlation analysis showed that circRNA_0001445 expression was positively correlated with lumbar spine BMD(r=0.427,P<0.001),femoral neck BMD(r=0.363,P<0.001)and hip BMD(r=0.435,P<0.001).Binary logistic regression showed high TC(OR=2.740,95%CI:1.473-5.099),low BMI(OR=0.674,95%CI:0.543-0.837)and circRNA_0001445(OR=0.019,95%CI:0.002-0.144)were risk factors for SOP,P<0.05.ROC curve analysis showed that circRNA_0001445 could distinguish SOP patients from normal bone mass patients(AUC=0.810,95%CI:0.728-0.892),osteopenia patients(AUC=0.756,95%CI:0.662-0.849)and non-SOP patients(AUC=0.783,95%CI:0.706-0.860).After 1 year of SOP treatment,the expression of circRNA_0001445 was higher than before(1.13±0.61 vs 2.14±0.61),P<0.001.Conclusion The circRNA_0001445 showed low expression in SOP,which has certain clinical value for diagnosis and treatment monitoring of SOP.